ArticleExperimental neurology2004
Remyelination, axonal sparing, and locomotor recovery following transplantation of glial-committed progenitor cells into the MHV model of multiple sclerosis.
Article in Experimental neurology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Cell replacement therapy with stem cells in multiple sclerosis, a systematic review.Human cell · 2024Pooled it
- Targeting Remyelination in Spinal Cord Injury: Insights and Emerging Therapeutic Strategies.CNS neuroscience & therapeutics · 2024Review
- Glial-restricted progenitor cells: a cure for diseased brain?Biological research · 2024Review
- Presentation of Human Neural Stem Cell Antigens Drives Regulatory T Cell Induction.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Cell transplantation to repair the injured spinal cord.International review of neurobiology · 2022Article
- Quetiapine Attenuates Schizophrenia-Like Behaviors and Demyelination in a MK-801-Induced Mouse Model of Schizophrenia.Frontiers in psychiatry · 2020Article
- Disrupted CXCR2 Signaling in Oligodendroglia Lineage Cells Enhances Myelin Repair in a Viral Model of Multiple Sclerosis.Journal of virology · 2019Article
- Promoting remyelination through cell transplantation therapies in a model of viral-induced neurodegenerative disease.Developmental dynamics : an official publication of the American Association of Anatomists · 2019Review
- Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.Molecular neurobiology · 2018Review
- Article
- Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease.Molecular neurobiology · 2016Review
- MicroRNA-155 enhances T cell trafficking and antiviral effector function in a model of coronavirus-induced neurologic disease.Journal of neuroinflammation · 2016Article
- Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis.Frontiers in immunology · 2016Review
- Sphingosine-1-phosphate receptor antagonism enhances proliferation and migration of engrafted neural progenitor cells in a model of viral-induced demyelination.The American journal of pathology · 2015Article
- Pluripotent stem cells for Schwann cell engineering.Stem cell reviews and reports · 2015Review
- Two-photon imaging of cellular dynamics in the mouse spinal cord.Journal of visualized experiments : JoVE · 2015Article
- Myelin damage and repair in pathologic CNS: challenges and prospects.Frontiers in molecular neuroscience · 2015Review
- Promoting remyelination: utilizing a viral model of demyelination to assess cell-based therapies.Expert review of neurotherapeutics · 2014Review
- Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis.Stem cells (Dayton, Ohio) · 2014Article
- FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.Journal of neuroinflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The behavior and myelinogenic properties of glial cells have been well documented following transplantation into regions of focal experimental demyelination in animal models. However, the ability of glial cell preparations to remyelinate in such models does not necessarily indicate that their transplantation into demyelinated lesions in clinical disease will be successful. One of the precluding factors in this regard is a greater understanding of the environmental conditions that will support transplant-mediated remyelination. In this study, we determined whether the complex and reactive CNS environment of the mouse hepatitis virus (MHV) model of multiple sclerosis (MS) could support transplant-mediated remyelination. Striatal neural precursors derived from postnatal day 1 mice were committed to a glial cell lineage and labeled. Immunohistochemical staining indicated that this population generated >93% glial cells following differentiation in vitro. Transplantation of glial-committed progenitor cells into the T8 spinal cord of MHV-infected mice demonstrating complete hindlimb paralysis resulted in migration of cells up to 12 mm from the implantation site and remyelination of up to 67% of axons. Transplanted-remyelinated animals contained approximately 2x the number of axons within sampled regions of the ventral and lateral columns as compared to non-transplanted animals, suggesting that remyelination is associated with axonal sparing. Furthermore, transplantation resulted in behavioral improvement. This study demonstrates for the first time that transplant-mediated remyelination is possible in the pathogenic environment of the MHV demyelination model and that it is associated with locomotor improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.